A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA
This study is a multicentre, open-label study of polatuzumab vedotin administered by
intravenous (IV) infusion in combination with standard doses of bendamustine (B) and
rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular
lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a
Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18
weeks for participants with DLBCL and 24 weeks for participants with FL.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society